The World's First FDA-Approved Artificial Heart
SynCardia Total Artificial Heart (STAH)
The SynCardia Total Artificial Heart is approved in the United States as a bridge to transplant for cardiac transplant-eligible candidates at risk of imminent death from biventricular failure.
How it works
The implanted ventricles connect to an external pneumatic driver system that powers the device and helps circulate blood to the lungs and body. The external driver may be:
70cc
50cc
Two available sizes support physician patient-selection decisions based on anatomy and clinical need.
Clinical benefits
For eligible patients, therapy goals may include:
- Restoration of circulation
- Hemodynamic support
- Stabilization while awaiting transplant
- Opportunity for mobilization and rehabilitation
- Potential transition to outpatient support when medically appropriate
- Clinical decisions are made by qualified physicians based on patient-specific factors
Indications
In the United States, the SynCardia Total Artificial Heart is indicated for use as a bridge to transplantation in cardiac transplant-eligible candidates at risk of imminent death from biventricular failure.
Please review full Instructions for Use for complete indications, contraindications, warnings, and precautions. View IFUs →
